COMP <GO>
SGRY vs JNJ // FREE CASH FLOW YIELD
Surgery Partners Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: SGRY 7
— JNJ 6
▲ FREE CASH FLOW YIELD LEADER: SGRY
LAST: $23.21 (0.00%) • MKT CAP: $3.04B
fcf-yield
6.44%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
fcf-yield
2.97%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SGRY VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SGRY | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 67.90% | -26.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | 25.50% | -15.60 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 9.7x | 18.5x | -8.80 | SGRY | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 6.44% | 2.97% | +3.47 | SGRY | /fcf-yield <GO> |
| Operating Margin | 45.80% | 34.70% | +11.10 | SGRY | /operating-margins <GO> |
| Net Profit Margin | -9.20% | 28.50% | -37.70 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 6.60% | 6.00% | +0.60 | SGRY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.67 | 5.59 | -4.92 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 7.20% | -0.30 | SGRY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 86.2 | 60.4 | +25.81 | SGRY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 1.08 | -0.09 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | 23.0x | -1.00 | SGRY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.04B | $662.49B | -$659.45B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SGRY REV | JNJ REV | SGRY GROSS % | JNJ GROSS % | SGRY FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $94.19B | — | 67.9% | $195.6M | $19.70B |
| FY 2024 | $0 | $88.82B | — | 69.1% | $209.7M | $19.84B |
| FY 2023 | $0 | $85.16B | — | 44.0% | $293.8M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SGRY // BETA 0.99
JNJ // BETA 1.08